Subtype
Malignant Infratentorial Neoplasm
CI-CAN-00007999Explore in graph →
99 active trials7 evidence items
- NCIt
- C4966
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007999Explore in graph →
Clinical trials
302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07492316 | RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)(PNOC020 rMB) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02040376 | Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | completed | Phase 3 | 24 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05230758 | Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour(Met Med Can) | recruiting | Phase 3 | 140 | Donald MabbottOTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy(PEACH) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830134 | Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback | recruiting | N/A | 40 | St. Jude Children's Research HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03251989 | Rare CNS Tumors Outcomes &Risk | completed | — | 326 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | recruiting | Phase 2 | 60 | Nationwide Children's HospitalOTHER | 5 | Sep 21, 2026 | clinicaltrials |
| NCT05535166 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | recruiting | Phase 2 | 130 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07087002 | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | recruiting | Phase 1 | 18 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06946680 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)(Peds IMPACT) | not yet recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | not yet recruiting | Phase 2 | 12 | Nationwide Children's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT05839379 | Targeted Pediatric High-Grade Glioma Therapy | recruiting | — | 350 | Nationwide Children's HospitalOTHER | 7 | Sep 8, 2026 | clinicaltrials |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06959979 | Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma | recruiting | Early Phase 1 | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07242963 | Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study | recruiting | — | 300 | Mohammad H. Abu ArjaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796061 | Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)(LIFT) | not yet recruiting | Phase 1 | 45 | Children's National Research InstituteOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06701812 | Digoxin Medulloblastoma Study | recruiting | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05382338 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | recruiting | Phase 3 | 225 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | withdrawn | — | 0 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2) | recruiting | Phase 3 | 433 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Aug 13, 2026 | clinicaltrials |
| NCT04696029 | DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | recruiting | Phase 2 | 118 | Giselle ShollerOTHER | 2 | Aug 12, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05057702 | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma(PNOC027) | recruiting | N/A | 74 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06822842 | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models | completed | — | 1,229 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07680439 | Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). | recruiting | Phase 2 | 75 | BrainChild Bio, IncINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | recruiting | Phase 1 | 56 | Baylor College of MedicineOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT06624371 | Atovaquone Combined With Radiation in Children With Malignant Brain Tumors(AflacBT2303) | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | not yet recruiting | Phase 2 | 79 | Nationwide Children's HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT03598244 | Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | active not recruiting | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2026 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials